Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | TGM1 | P22735 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9528983 | 0.85 | CYP1A2 (0.42) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL9431644 | 0.83 | KMT2A (0.51) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| SCHEMBL2276946 | 0.80 | KMT2A (0.45) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| SCHEMBL9690746 | 0.72 | — | — | |
| SCHEMBL9431323 | 0.71 | FFAR1 (0.44) | ALDH1A1MAPTKMT2AMEN1CYP2A6 | |
| SCHEMBL2083549 | 0.67 | ALDH1A1 (0.39) | ALDH1A1MAPTKMT2AHTTCYP2A6 | |
| SCHEMBL23449026 | 0.66 | LTB4R (0.35) | ALDH1A1MAPTKMT2AMEN1SRC | |
| SCHEMBL1121674 | 0.65 | NPC1 (0.53) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| SCHEMBL23450058 | 0.63 | ALDH1A1 (0.62) | ALDH1A1MAPTKMT2AMEN1PKM | |
| SCHEMBL9474580 | 0.63 | CYP2A6 (0.39) | ALDH1A1MAPTKMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399156-B1 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS (AN) | 2006-11-22 | — | — | EP | disclosed |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | LABORATOIRES SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1399156-A2 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | Applied Research Systems ARS Holding N.V. (AN) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002102359-A2 | ALKYLIDENE PYRAZOLIDINEDIONE DERIVATIVES AND USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | G6PC1, PPM1D, PTPRS | ALDH1A1 721/4885MAPT 4820/4885KMT2A 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.